Table 3.

Expert consensus recommendations on the use of individual disease-modifying drugs (DMDs) in women planning a pregnancy according to disease activity

Patient with active MS	Patient with highly active MS
High consensus  Interferon β  Glatiramer acetate	High consensus  Cladribine tablets  Natalizumab  Ocrelizumab
Moderate consensus  Dimethyl fumarate  Cladribine tablets	Moderate consensus  Alemtuzumab
Low consensus  Natalizumab  Ocrelizumab	Low consensus  Dimethyl fumarate

Consensus levels were as follows: high, 8 or more physicians; moderate, 4–7 physicians; low, 1–3 physicians